Details of the Drug

General Information of Drug (ID: DMP3X6Q)

Drug Name
Dacetuzumab
Synonyms SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Terminated [1]
Non-hodgkin lymphoma 2B33.5 Terminated [1]
Drug Type
Monoclonal antibody
Cross-matching ID
DrugBank ID
DB12589
TTD ID
D0PU8Z
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TNF related activation protein (CD40LG) TTIJP3Q CD40L_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TNF related activation protein (CD40LG) DTT CD40LG 8.02E-01 -0.13 -0.7
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
2 A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35.